Second generation small molecule inhibitors, such as ceritinib, alectinib, and brigatinib, have been developed and studied in ALK-positive NSCLC [96], with clinical trials for these agents in ALK-positive ALCL currently undergoing recruitment (Table 2). The gene discussed is ALK; the disease is non-small cell lung carcinoma.